TY - JOUR
T1 - Application of human amniotic mesenchymal cells as an allogeneic transplantation cell source in bone regenerative therapy
AU - Tsuno, Hiroaki
AU - Yoshida, Toshiko
AU - Nogami, Makiko
AU - Koike, Chika
AU - Okabe, Motonori
AU - Noto, Zenko
AU - Arai, Naoya
AU - Noguchi, Makoto
AU - Nikaido, Toshio
N1 - Funding Information:
This work was supported by the Japan Society for the Promotion of Science KAKENHI ( 22791966 ).
PY - 2012/12/1
Y1 - 2012/12/1
N2 - Autogenous mesenchymal stem cells (MSCs) have therapeutic applications in bone regenerative therapy due to their pluripotency. However, the ability of MSCs to proliferate and differentiate varies between donors. Furthermore, alternative sources of MSCs are required for patients with contraindications to autogenous cell therapy. The aim of this study was to evaluate the potential of mesenchymal cells from the human amniotic membrane (HAM) as a source of cells for allogeneic transplantation in bone regenerative therapy. Cells that retained a proliferative capacity of more than 50 population doubling level were distinguished from other HAM cells as HAMα cells and induced to osteogenic status - their in vivo osteogenesis was subsequently investigated in rats. It was found that HAMα cells were spindle shaped and were positive for MSC markers and negative for hematopoietic stem cell markers. Alkaline phosphatase activity and calcium deposition increased with osteogenic status of HAMα cells. The expression of osteocalcin mRNA was increased in HAMα cells cultured on calcium phosphate scaffolds. Moreover, xenografted HAMα cells remained viable and produced extracellular matrix for several weeks. Thus, this study suggests that human amniotic mesenchymal cells possess osteogenic differentiation potential and could be applied to allogeneic transplantation in bone regenerative therapy.
AB - Autogenous mesenchymal stem cells (MSCs) have therapeutic applications in bone regenerative therapy due to their pluripotency. However, the ability of MSCs to proliferate and differentiate varies between donors. Furthermore, alternative sources of MSCs are required for patients with contraindications to autogenous cell therapy. The aim of this study was to evaluate the potential of mesenchymal cells from the human amniotic membrane (HAM) as a source of cells for allogeneic transplantation in bone regenerative therapy. Cells that retained a proliferative capacity of more than 50 population doubling level were distinguished from other HAM cells as HAMα cells and induced to osteogenic status - their in vivo osteogenesis was subsequently investigated in rats. It was found that HAMα cells were spindle shaped and were positive for MSC markers and negative for hematopoietic stem cell markers. Alkaline phosphatase activity and calcium deposition increased with osteogenic status of HAMα cells. The expression of osteocalcin mRNA was increased in HAMα cells cultured on calcium phosphate scaffolds. Moreover, xenografted HAMα cells remained viable and produced extracellular matrix for several weeks. Thus, this study suggests that human amniotic mesenchymal cells possess osteogenic differentiation potential and could be applied to allogeneic transplantation in bone regenerative therapy.
KW - Allogeneic cell transplantation
KW - Amniotic mesenchymal cells
KW - Bone regenerative therapy
KW - Calcium phosphate scaffold
KW - Mesenchymal stem cells
UR - http://www.scopus.com/inward/record.url?scp=84866012609&partnerID=8YFLogxK
U2 - 10.1016/j.msec.2012.07.021
DO - 10.1016/j.msec.2012.07.021
M3 - 学術論文
AN - SCOPUS:84866012609
SN - 0928-4931
VL - 32
SP - 2452
EP - 2458
JO - Materials Science and Engineering C
JF - Materials Science and Engineering C
IS - 8
ER -